Who should be really considered as a poor mobilizer in the plerixafor era?-Reference-Cited by-同舟云学术

Who should be really considered as a poor mobilizer in the plerixafor era?

Published:2012-08 Issue:1 Volume:47 Page:27-32
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Andreola Giovanna,Vanazzi Anna,Radice Davide,Babic Aleksandra,Rabascio Cristina,Negri Mara,Martinelli Giovanni,Laszlo Daniele

Publisher

Elsevier BV

Subject

Hematology

Reference39 articles.

1. Role of autologous stem-cell transplantation in multiple myeloma;Attal;Best Pract Res Clin Haematol,2007

2. Current treatment standards and emerging strategies in mantle cell lymphoma;Dreyling;Ame Soc Hematol Edu Program,2009

3. Role of hematopoietic stem cell transplant in the management of follicular lymphoma;Foster;Oncologist,2009

4. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma Part 2. Novel therapeutic strategies;Hernandez-Ilizaliturri;Oncology – New York,2009

5. Controversies in the treatment of lymphoma with autologous transplantation;Moskowitz;Oncologist,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic issues in stem cell mobilization;Transfusion and Apheresis Science;2023-12

2. Correlation of Body Mass Index and Proinflammatory Cytokine Levels with Hematopoietic Stem Cell Mobilization;Journal of Clinical Medicine;2022-07-18

3. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis;Bone Marrow Transplantation;2021-03-22

4. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center;Journal of Clinical Apheresis;2019-01-29

5. Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule;Leukemia & Lymphoma;2017-10-30